Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin detemir Clear all
Completed Phase 4 Interventional Results available

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

NCT00634842
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 3, 2026, 6:54 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

NCT06419777
View directory record Official record
Conditions
Gestational Diabetes, Pregnancy Related
Interventions
Insulin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

NCT00773279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexTouch®, FlexPen®
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
65
States / cities
Burlingame, California • Concord, California • Encino, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

NCT00457093
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
glargine, detemir
Drug
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

NCT00978627
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Terminated Not applicable Interventional

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Degludec, Standard long-acting
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days

NCT01547169
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Placebo Comparator, insulin detemir
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

NCT01043510
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

NCT00322257
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
inhaled human insulin, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

NCT01165684
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

NCT01232491
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Dietary regimen
Drug · Dietary Supplement
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Detemir: Role in Type 1 Diabetes

NCT00564395
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01513473
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00909480
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
71
States / cities
Litchfield Park, Arizona • Searcy, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

NCT01232946
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
liraglutide, insulin detemir, liraglutide plus insulin detemir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 3, 2026, 6:54 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

mHealth Titration and Management

NCT03908762
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Complication
Interventions
iSage App with connected glucometer, Magnet
Device · Behavioral
Lead sponsor
Amalgam Rx, Inc.
Industry
Eligibility
21 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 3, 2026, 6:54 PM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

NCT01837680
View directory record Official record
Conditions
Diabetes, Gestational, Diabetes, Type 2
Interventions
Insulin
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 3, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 3, 2026, 6:54 PM EDT